Literature DB >> 2442831

Improved myocardial protection by creatine phosphate in cardioplegic solution. An in vivo study in the pig during normothermic ischemia.

S Thelin, J Hultman, G Ronquist, C Juhlin, H E Hansson, P G Lindgren.   

Abstract

The effect of creatine phosphate in potassium cardioplegia was studied in a pig heart model in vivo. Fifteen pigs divided into two groups were placed on cardiopulmonary bypass and subjected to 1 hour of cardioplegic arrest at normothermia. In group I (control), in which a potassium cardioplegic solution was used, only two out of eight animals could successfully be weaned from bypass. In group II, on the other hand, in which creatine phosphate (10 mmol/l) was added to the cardioplegic solution, six out of seven animals could be weaned from bypass and the heart performance assessed by volume loading. Group II also exhibited better maintenance of high-energy phosphates during ischemia, with significantly higher adenylate charge potential, than group I. In all animals weaned from bypass--two in group I and six in group II--the ventricular performance was decreased compared with that before induction of ischemia. The results indicate that creatine phosphate could be an effective constituent in potassium cardioplegia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442831     DOI: 10.1055/s-2007-1020217

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  2 in total

Review 1.  Augmentation of Creatine in the Heart.

Authors:  Sevasti Zervou; Hannah J Whittington; Angela J Russell; Craig A Lygate
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  Protective Effect of Creatine Elevation against Ischaemia Reperfusion Injury Is Retained in the Presence of Co-Morbidities and during Cardioplegia.

Authors:  Hannah J Whittington; Debra J McAndrew; Rebecca L Cross; Stefan Neubauer; Craig A Lygate
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.